Stephen L. Eck - 07 Feb 2025 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Medical Officer
Signature
Beth A. Smith, Attorney-in-fact
Issuer symbol
MGNX
Transactions as of
07 Feb 2025
Net transactions value
-$8,611
Form type
4
Filing time
11 Feb 2025, 20:34:43 UTC
Previous filing
20 Feb 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $0 +11,168 +114% $0.000000 20,966 08 Feb 2025 Direct F1
transaction MGNX Common Stock Tax liability $8,611 -3,312 -16% $2.60 17,654 08 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee Stock Option (right to buy) Award $0 +113,000 $0.000000 113,000 07 Feb 2025 Common Stock 113,000 $2.60 Direct F2
transaction MGNX Restricted Stock Unit Award $0 +19,000 $0.000000 19,000 07 Feb 2025 Common Stock 19,000 Direct F1, F3
transaction MGNX Restricted Stock Unit Options Exercise $0 -11,168 -33% $0.000000 22,332 08 Feb 2025 Common Stock 11,168 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2024 the reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis.
F2 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F3 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.